RUBY

Rubius Therapeutics to Present Trials in Progress Poster on the Phase 1 Clinical Trial of RTX-321 for HPV 16-Positive Cancers at the 2021 American Society of Clinical Oncology Annual Meeting

Rubius Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

Rubius Therapeutics Presents Initial Clinical Results from the Ongoing Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors at the American Association of Cancer Research Virtual Annual Meeting

Implied Volatility Surging for Rubius Therapeutics (RUBY) Stock Options

Rubius Therapeutics Prices Upsized Public Offering of Common Stock

Rubius Therapeutics Announces Proposed Public Offering of Common Stock

Rubius Therapeutics Stock Trading Higher On Positive Efficacy, Safety RTX-240 Data In Solid Tumor Study